Carol M. Mangione, MD

Chief, General Internal Medicine

Carol M. Mangione, M.D., M.S.P.H., is the chief of the Division of General Internal Medicine and Health Services Research and the Barbara A. Levey, MD, and Gerald S. Levey, MD, endowed chair in medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Department of Medicine Executive Vice Chair for Health Equity and Health Services Research. She is also a distinguish professor of public health at the UCLA Fielding School of Public Health and director of the UCLA Resource Center for Minority Aging Research/Center for Health Improvement of Minority Elders, director of the UCLA CTSI Workforce Development Program. Dr. Mangione is also a practicing primary care physician in the UCLA Faculty Practice Group.

Dr. Mangione’s areas of expertise include diabetes, diabetes prevention, health disparities, aging, public health, health insurance benefit design, and public health policy. She is a member of numerous professional societies and organizations, including the National Academy of Medicine, American Society of Clinical Investigation, the Society for General Internal Medicine, the American Geriatrics Society, AcademyHealth, the American Diabetes Association, and the American College of Physicians.
Dr. Mangione was the principal investigator for “The Diabetes Health Plan: A System-Level Intervention to Prevent and Treat Diabetes,” funded by the CDC and NIDDK to evaluate the effectiveness of the first disease-specific health plan in the United States. This work focused on studying the influence of benefit design on prevention of diabetes, adherence to medications, and control of cardiovascular risk factors among persons with diabetes. Dr. Mangione is the principal investigator of the “Managing Your Medication for Education and Daily Support” (UCMyRx) program, which embeds clinical pharmacists in primary care practices to enhance communication, educate, and improve medication adherence for patients with poor control of cardiovascular risk factors and for older adults who have polypharmacy and are struggling with adherence to their medications. She was also co-principal investigator of a grant from NIDDK, “A Cluster-Randomized Trial of Pharmacist-Coordinated Implementation of the Diabetes Prevention Program,” which evaluated a primary care–based program that uses a shared decision making tool to help patients with prediabetes learn about the condition and make treatment choices that will reduce their chance of developing diabetes. She also was a co-principal investigator on an award from the CDC and NIDDK entitled “A Partnered Evaluation of United Health Care’s Medicaid Plan Innovations for Diabetes Patients,” which is evaluating health plan–level innovations designed to improve the care of patients with chronic conditions in the Medicaid expansion population and in 2020 was awarded by the  CDC and NIDDK a project entitled “A Pragmatic Nationwide  RCT of Coordinated Medical, Behavioral, and Social Services to Improve Care and Utilization among High-Cost, High-Need Insured Patients with Diabetes”.

Dr. Mangione was recognized in 2013 with the UCLA Exceptional Physician Award. She has dedicated a substantial proportion of her career to helping entry and mid-level faculty reach their full potential, and in recognition of this in 2022 she was named an inaugural member of the campuswide UCLA Faculty Mentoring Society and also was the 2022 recipient of the Alan M Fogelman Mentorship Award.

Dr. Mangione has authored more than 350 peer-reviewed articles and seven book chapters.

Dr. Mangione received her B.S. from the University of Michigan, Ann Arbor. She earned her M.D. at the University of California, San Francisco, and completed her residency at University of California Affiliated Hospitals. Dr. Mangione earned her M.S.P.H. from the Harvard School of Public Health and has completed fellowships at Harvard Medical School.

Dr. Mangione was appointed as chair of the U.S. Preventive Services Task Force in March 2022. She previously served as a member from January 2016 through December 2019 and as vice chair from March 2020 through March 2022.